Ads
related to: docetaxel and carboplatin breast cancer triple negative prognosis survival rate- Request A Rep
Request a Representative & Discover
More About Treatment Option.
- Clinical Trial Results
Learn About Clinical Trial Results
In Patients Like Yours.
- Ordering Information
Find Out More About Ordering
A Treatment For Your Patients.
- Prescription Info
Find Dosing Guides & Safety
Information Here.
- Nurses Station
Explore Resources Made For Nurses
To Learn About A mTNBC Treatment.
- Clinical Trial Design
Learn More About Clinical Trial
And Study Results Today.
- Request A Rep
Search results
Results From The WOW.Com Content Network
TCH is a chemotherapy regimen consisting of Taxotere (docetaxel), carboplatin and Herceptin (trastuzumab), which is used to treat breast cancer. References
Triple-negative breast cancer comprises 15–20% of all breast cancer cases [3] and affects more young women or women with a mutation in the BRCA1 gene than other breast cancers. [4] Triple-negative breast cancers comprise a very heterogeneous group of cancers. TNBC is the most challenging breast cancer type to treat. [5]
breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic) TAD tioguanine, cytarabine (ara-C), daunorubicin: acute myeloid leukemia: TC or CT docetaxel (Taxotere), cyclophosphamide: breast cancer: TCH: docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin) breast cancer with positive HER2/neu receptor TCHP
The American Cancer Society reports 5-year relative survival rates of over 70% for women with stage 0-III breast cancer with a 5-year relative survival rate close to 100% for women with stage 0 or stage I breast cancer. The 5-year relative survival rate drops to 22% for women with stage IV breast cancer. [3]
Neoadjuvant chemotherapy is given before surgery to slow the growth of a fast-growing cancer or to shrink the size of a larger breast cancer. [1] It is frequently used to treat locally advanced cancers, cancers that at the time of diagnosis are too large to be removed by surgery, which can then be removed with less extensive surgery. [2]
Conversely, triple negative cancer (i.e. no positive receptors), lacking targeted treatments, now has a comparatively poor prognosis. [42] [43] Androgen receptor is expressed in 80-90% of ER+ breast cancers and 40% of "triple negative" breast cancers. Activation of androgen receptors appears to suppress breast cancer growth in ER+ cancer while ...
Ads
related to: docetaxel and carboplatin breast cancer triple negative prognosis survival rate